Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man.
Tepoxalin, a novel inhibitor of cyclooxygenase (CO) and 5-lipoxygenase (5-LO), was investigated for biochemical activity and pharmacokinetics in two studies. Study I was a 4-period, double-blind, randomized, single rising dose using 2 alternating panels (A, B) with interspersed placebo design (A: 25, 100, 400 mg, B: 50, 200, 800 mg p.o.). Study II was a 3-panel, randomized, placebo-controlled, double-blind, multiple dose study (A: 100 mg, B: 200 mg, C: 400 mg). In both studies, CO inhibition was assessed by generation of serum thromboxane (TxB2), 5-LO activity by LTB4 production ex vivo in Caionophore-stimulated blood. Plasma drug concentrations were assayed by HPLC for tepoxalin and its identified acid metabolite. It was found in both studies that at all dose levels the TxB2 generation was markedly suppressed (> 95% 2 h postdose). In study I, at 2 h postdose, % inhibition of LTB4 biosynthesis was marginal for the 3 lower doses but significant at 200 (14%), 400 (25%) and 800 mg (43%). In study II, the only significant inhibition occurred at the 400 mg dose at 6 h postdose on day 1 (17%) and on day 8 at 4, 6 and 8 h postdose (32, 42 and 32% respectively). In both studies and at all doses, plasma concentrations of tepoxalin varied widely between subjects. Linearity between plasma concentrations and dose could not be ascertained, and correlation between drug plasma levels and effect on LTB4 synthesis was poor. Single doses up to 800 mg and multiple doses up to 400 mg of tepoxalin were generally well tolerated.
Depré
M
M
Centre for Clinical Pharmacology, Katholieke Universiteit Leuven, Belgium.
Van Hecken
A
A
Verbesselt
R
R
Verpooten
G A
GA
Arnout
J
J
Brunner
F
F
Jurgens
A
A
Pousset
V
V
Chow
A
A
Baldauf
C
C
Vermylen
J
J
De Broe
M
M
De Schepper
P J
PJ
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics* / Q000494:pharmacology*; D019540:Area Under Curve; D016861:Cyclooxygenase Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004311:Double-Blind Method; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007975:Leukotriene B4 / Q000096:biosynthesis / Q000097:blood; D016859:Lipoxygenase Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology*; D008111:Liver Function Tests; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011720:Pyrazoles / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000096:biosynthesis / Q000097:blood
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D011720:Pyrazoles; D007975:Leukotriene B4; D013929:Thromboxane B2; C073135:tepoxalin